# Carrier Biomed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carrier-biomed

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.carrierbiomed.com
- Latest round: Series A (Dec 28, 2022)
- Investors on record: 4

## About

Based in Suzhou, China, and founded in 2019, Carrier (Suzhou) Biomedical Co., Ltd., trading as Carrier Biomed operates as a biopharmaceutical company, focusing on exosome technology development and clinical translation. The co-founder as well as the CEO of the company, Zhentao Li, is the member of Special Committee on Research and Application of Extracellular Vesicles of the Chinese Society of Research Hospitals. In 2021, Carrier Biomed was awarded as an outstanding enterprise in the China Innovation and Entrepreneurship Competition. In December 2025, Carrier Biomed raised Series A+ funding.
The company has a platform for exosome isolation and multiple pipelines for large-scale multi-center clinical studies, including early blood diagnosis of neurodegenerative diseases, early diagnosis of tumors and dynamic monitoring of late-staged treatments. Tumor pipeline can be used to assist in early screening, differential diagnosis, disease detection, efficacy prediction and prognosis of malignant tumors.
Revenue is generated from commercialization of exosome diagnostic products and clinical services for hospitals and research institutions.

## Funding rounds

- Series A, Dec 28, 2022 — Triwise Capital, Rivercity Investment, Leader Venture Capital, Qingnuo Capital

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series A
- Rivercity Investment (https://capitalatlas.ai/funds/rivercity-investment) — Series A
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series A
- Qingnuo Capital — Series A